The use of bone morphogenetic protein gene therapy in craniofacial bone repair

Tord D. Alden, Elisa J. Beres, Jeffrey S. Laurent, Johnathan A. Engh, Subinoy Das, Scott London, John A. Jane, Sarah B. Hudson, Gregory A. Helm

Research output: Contribution to journalArticle

Abstract

Bone morphogenetic proteins (BMPs) are capable of inducing endochondral bone formation when applied on biologic carriers in numerous mammalian in vivo assay systems. Bone morphogenetic protein gene therapy is also currently being developed to promote osteogenesis for clinical indications such as spinal fusions, craniofacial bone loss, and osteoporosis. In this study, critical-sized mandibular defects were treated with a control adenoviral vector (Ad-β-gal), a BMP-2 adenoviral vector (Ad-BMP-2), or a BMP-9 adenoviral vector (Ad-BMP-9). Gross tissue examination, radiographic analysis, and histologic analysis demonstrated significant bony healing in the BMP treated groups compared to controls. Osteogenesis was limited to the bony defect, without extension into the surrounding soft tissues. The study suggests that with further development, BMP gene therapy may be potentially useful for repair of bony defects in the craniofacial region.

Original languageEnglish (US)
Pages (from-to)24-30
Number of pages7
JournalJournal of Craniofacial Surgery
Volume11
Issue number1
StatePublished - Jan 2000
Externally publishedYes

Fingerprint

Bone Morphogenetic Proteins
Genetic Therapy
Osteogenesis
Bone and Bones
Growth Differentiation Factor 2
Bone Morphogenetic Protein 2
Spinal Fusion
Osteoporosis

Keywords

  • Adenovirus
  • BMP-2
  • BMP-9
  • Gene therapy
  • Osteogenesis

ASJC Scopus subject areas

  • Surgery

Cite this

Alden, T. D., Beres, E. J., Laurent, J. S., Engh, J. A., Das, S., London, S., ... Helm, G. A. (2000). The use of bone morphogenetic protein gene therapy in craniofacial bone repair. Journal of Craniofacial Surgery, 11(1), 24-30.

The use of bone morphogenetic protein gene therapy in craniofacial bone repair. / Alden, Tord D.; Beres, Elisa J.; Laurent, Jeffrey S.; Engh, Johnathan A.; Das, Subinoy; London, Scott; Jane, John A.; Hudson, Sarah B.; Helm, Gregory A.

In: Journal of Craniofacial Surgery, Vol. 11, No. 1, 01.2000, p. 24-30.

Research output: Contribution to journalArticle

Alden, TD, Beres, EJ, Laurent, JS, Engh, JA, Das, S, London, S, Jane, JA, Hudson, SB & Helm, GA 2000, 'The use of bone morphogenetic protein gene therapy in craniofacial bone repair', Journal of Craniofacial Surgery, vol. 11, no. 1, pp. 24-30.
Alden, Tord D. ; Beres, Elisa J. ; Laurent, Jeffrey S. ; Engh, Johnathan A. ; Das, Subinoy ; London, Scott ; Jane, John A. ; Hudson, Sarah B. ; Helm, Gregory A. / The use of bone morphogenetic protein gene therapy in craniofacial bone repair. In: Journal of Craniofacial Surgery. 2000 ; Vol. 11, No. 1. pp. 24-30.
@article{da49bc3f9f6e4fb9b670ebd2056519e6,
title = "The use of bone morphogenetic protein gene therapy in craniofacial bone repair",
abstract = "Bone morphogenetic proteins (BMPs) are capable of inducing endochondral bone formation when applied on biologic carriers in numerous mammalian in vivo assay systems. Bone morphogenetic protein gene therapy is also currently being developed to promote osteogenesis for clinical indications such as spinal fusions, craniofacial bone loss, and osteoporosis. In this study, critical-sized mandibular defects were treated with a control adenoviral vector (Ad-β-gal), a BMP-2 adenoviral vector (Ad-BMP-2), or a BMP-9 adenoviral vector (Ad-BMP-9). Gross tissue examination, radiographic analysis, and histologic analysis demonstrated significant bony healing in the BMP treated groups compared to controls. Osteogenesis was limited to the bony defect, without extension into the surrounding soft tissues. The study suggests that with further development, BMP gene therapy may be potentially useful for repair of bony defects in the craniofacial region.",
keywords = "Adenovirus, BMP-2, BMP-9, Gene therapy, Osteogenesis",
author = "Alden, {Tord D.} and Beres, {Elisa J.} and Laurent, {Jeffrey S.} and Engh, {Johnathan A.} and Subinoy Das and Scott London and Jane, {John A.} and Hudson, {Sarah B.} and Helm, {Gregory A.}",
year = "2000",
month = "1",
language = "English (US)",
volume = "11",
pages = "24--30",
journal = "Journal of Craniofacial Surgery",
issn = "1049-2275",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The use of bone morphogenetic protein gene therapy in craniofacial bone repair

AU - Alden, Tord D.

AU - Beres, Elisa J.

AU - Laurent, Jeffrey S.

AU - Engh, Johnathan A.

AU - Das, Subinoy

AU - London, Scott

AU - Jane, John A.

AU - Hudson, Sarah B.

AU - Helm, Gregory A.

PY - 2000/1

Y1 - 2000/1

N2 - Bone morphogenetic proteins (BMPs) are capable of inducing endochondral bone formation when applied on biologic carriers in numerous mammalian in vivo assay systems. Bone morphogenetic protein gene therapy is also currently being developed to promote osteogenesis for clinical indications such as spinal fusions, craniofacial bone loss, and osteoporosis. In this study, critical-sized mandibular defects were treated with a control adenoviral vector (Ad-β-gal), a BMP-2 adenoviral vector (Ad-BMP-2), or a BMP-9 adenoviral vector (Ad-BMP-9). Gross tissue examination, radiographic analysis, and histologic analysis demonstrated significant bony healing in the BMP treated groups compared to controls. Osteogenesis was limited to the bony defect, without extension into the surrounding soft tissues. The study suggests that with further development, BMP gene therapy may be potentially useful for repair of bony defects in the craniofacial region.

AB - Bone morphogenetic proteins (BMPs) are capable of inducing endochondral bone formation when applied on biologic carriers in numerous mammalian in vivo assay systems. Bone morphogenetic protein gene therapy is also currently being developed to promote osteogenesis for clinical indications such as spinal fusions, craniofacial bone loss, and osteoporosis. In this study, critical-sized mandibular defects were treated with a control adenoviral vector (Ad-β-gal), a BMP-2 adenoviral vector (Ad-BMP-2), or a BMP-9 adenoviral vector (Ad-BMP-9). Gross tissue examination, radiographic analysis, and histologic analysis demonstrated significant bony healing in the BMP treated groups compared to controls. Osteogenesis was limited to the bony defect, without extension into the surrounding soft tissues. The study suggests that with further development, BMP gene therapy may be potentially useful for repair of bony defects in the craniofacial region.

KW - Adenovirus

KW - BMP-2

KW - BMP-9

KW - Gene therapy

KW - Osteogenesis

UR - http://www.scopus.com/inward/record.url?scp=0033959211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033959211&partnerID=8YFLogxK

M3 - Article

C2 - 11314095

AN - SCOPUS:0033959211

VL - 11

SP - 24

EP - 30

JO - Journal of Craniofacial Surgery

JF - Journal of Craniofacial Surgery

SN - 1049-2275

IS - 1

ER -